According to SPER Market Research, the Global Glioblastoma Multiforme Treatment Market is categorized as a grade IV disease by the WHO. Given that they are among the most often clinically diagnosed oncological tutors of the central nervous system (CNS), a variety of historical records have covered the description and growth of beliefs regarding these tumors’ market is anticipated to develop as a result of a number of factors, including improved R&D, favorable regulatory circumstances, and the rising prevalence of glioblastoma multiforme. A strong pipeline is likely to have a significant impact on the glioblastoma multiforme therapeutics market during the anticipated timeframe (GBM). The probability of brain tumors is anticipated to fuel market growth throughout the course of the anticipated time frame. Brain cancer is among the most fatal forms of the disease.
Because of COVID-19, the market for glioblastoma treatments has suffered. Numerous ICU resources, such as ventilators, personal protective equipment, and medical personnel, were shifted to COVID-19 cases during the COVID-19 pandemic, which resulted in the suspension of surgical neuro-oncology therapies. The capacity to deliver necessary cancer patients with efficient medical care was insecure during the pandemic. Furthermore, it appears that those who have glioblastoma are more vulnerable to COVID-19 infection, which forced the postponement of procedures and treatments. As a result, the market is significantly impacted by the global glioma treatment market.
Glioblastoma Multiforme Treatment Market Overview:
Forecast CAGR (2022-2032): 9.04%.
Forecast Market Size (2032): 6.05 billion.
Impact of COVID-19 on the Global Glioblastoma Multiforme Treatment Market:
Because of COVID-19, the market for glioblastoma treatments has suffered. Numerous ICU resources, such as ventilators, personal protective equipment, and medical personnel, were shifted to COVID-19 cases during the COVID-19 pandemic, which resulted in the suspension of surgical neuro-oncology therapies. The capacity to deliver necessary cancer patients with efficient medical care was insecure during the pandemic. Furthermore, it appears that those who have glioblastoma are more vulnerable to COVID-19 infection, which forced the postponement of procedures and treatments. Therefore, the market is significantly impacted by the global glioma treatment market.
Request For Free sample report @ https://www.sperresearch.com/report-store/glioblastoma-multiforme-treatment-market.aspx?sample=1
Glioblastoma Multiforme Treatment Market Key Segments Covered:
The SPER Market Research report seeks to give market dynamics, demand, and supply forecasts for the years up to 2032. This report contains statistics on product type segment growth estimates and forecasts.
By Drug Class:
- Bevacizumab.
- Cars tone Wafers.
- Limestone
- Temozolomide
- Others.
By Treatment:
- Chemotherapy.
- Immunotherapy.
- Radiation Therapy.
- Surgery.
- Targeted Therapy.
- Tumor Treating Field (TTF) Therapy.
By End Use:
- Ambulatory Surgical Centers.
- Clinics.
- Surgery.
By Region:
- North America
- Europe
- Asia-Pacific
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends, and strategies for this market. It traces the market's historic and forecast market growth by geography.
Glioblastoma Multiforme Treatment Market Key Players:
The Global Glioblastoma Multiforme Treatment Market study provides market data by competitive landscape, revenue analysis, market segments and detailed analysis of key market players such as; Amgen, Inc., Amneal Pharmaceuticals, Arbor Pharmaceuticals, LLC, F. Hoffmann-La Roche Ltd., Karyopharm Therapeutics, Inc., Merck & Co., Inc., Pfizer Inc., Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.), Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd.
For More Information, refer to below link: -
Glioblastoma Multiforme Treatment Market Size,
Related Reports:
Follow Us –
LinkedIn | Instagram | Facebook | Twitter
Contact Us:
Sara Lopes, Business Consultant – USA
SPER Market Research
+1-347-460-2899
ASCO: axi-cel in ZUMA-1Abstract No : 8012Abstract Type : Oral Abstract SessionIndication : Diffused Large B-Cell Lymphoma (DLBCL)Intervention : YescartaCompany : Kite, a Gilead CompanyTechnology : CAR T Cell TherapyBased on this limited sample size, reTx with axi-cel may have clinical efficacy, although transient, in some pts, especially those who achieve CR with 1st Tx.
CAR T cell expansion and severe CRS and NEs may be attenuated at reTx.
Further studies with additional pts are needed to confirm these results.View More: https://www.delveinsight.com/asco-conference/article/zuma-1 GSK: Cell Therapy and Next-generation Immuno-oncologyAt this year’s ASCO meeting, they will showcase presentations on investigational therapies, including belantamab mafodotin, an antibody-drug conjugate for multiple myeloma, and GSK3359609, an inducible T-cell co-stimulator (ICOS) agonist for patients with head and neck cancer.View More: https://www.delveinsight.com/asco-conference/article/gsk-cell-therapy-next-generation-immuno-oncology IMbrave150 TRIAL of AtezolizumabAtezo + Bev HCCIMbrave150 demonstrated statistically significant and clinically meaningful improvement in both OS and PFS with atezo + bev vs sor in pts with unresectable HCC who have not received prior systemic therapy.
Pts achieved CRs regardless of poor prognostic factors or etiology.
Atezo + bev may be a practice-changing treatment for pts with unresectable HCC.View More: https://www.delveinsight.com/asco-conference/article/imbrave150 ASCO: KEYNOTE-204Abstract No : 8005Abstract Type : Oral Abstract SessionIndication : Hodgkin’s Lymphoma (HL)Intervention : PembrolizumabCompany : Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.Technology : ImmunocheckpointIn pts with R/R cHL, pembro was superior to BV and demonstrated statistically significant and clinically meaningful improvement in PFS across all subgroups, with safety consistent with previous reports.
Pembro monotherapy should be standard of care for this pt population with R/R/cHL.View More: https://www.delveinsight.com/asco-conference/article/NCT02684292 ASCO: INO-5401 + INO-9012 with CemiplimabAbstract No : 2514Abstract Type : Oral Abstract SessionIndication : Glioblastoma MultiformeIntervention : INO-5401 and INO-9012 + CemiplimabCompany : Inovio PharmaTechnology : T cell therapy/Monoclonal AntibodyINO-5401 + INO-9012 in combination with cemiplimab and RT/TMZ has an acceptable safety profile, is immunogenic and may show a survival advantage in patients with newly-diagnosed GBM.View Report: https://www.delveinsight.com/asco-conference/article/NCT03491683
